Health & Bio
Bayer buys Perfuse vision-implant developer for up to $2.45B
Bayer acquired Perfuse Therapeutics and PER-001, an intraocular implant. Deal: $300M upfront plus up to $2.45B in milestones. Targets glaucoma and diabetic retinopathy.
Primary sources · 2